Trial Profile
A phase II IV to oral switch trial to investigate APX-001 in invasive candidiasis
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 08 May 2018
Price :
$35
*
At a glance
- Drugs Fosmanogepix (Primary)
- Indications Invasive candidiasis
- Focus Therapeutic Use
- 30 Apr 2018 According to an Amplyx Pharmaceuticals media release, this trial is expected to initiate this year
- 04 Aug 2017 New trial record
- 02 Aug 2017 According to an Amplyx Pharmaceuticals media release, this trial is expected to initiate later this year.